Table 2.
Baseline characteristics of patients in the platelet sub-study
| No Diabetes Mellitus (n=25) |
Continue group (n=25) |
Hold group (n=25) |
p- value* |
p- value** |
|
|---|---|---|---|---|---|
| Age (years) | 65 [61–77] | 65 [63–71] | 68 [63–73] | 0.52 | 0.28 |
| Men | 23 (92%) | 25 (100%) | 25 (100%) | 0.13 | 1.0 |
| White | 20 (80%) | 19 (76%) | 20 (80%) | 0.38 | 0.34 |
| Black | 5 (20%) | 4 (16%) | 5 (20%) | ||
| Hispanic | 0 | 2 (8%) | 0 | ||
| Body mass index (kg/m2) | 29 [27–32] | 34 [30–36] | 30 [27–33] | 0.03 | 0.04 |
| Abdominal circumference (inch) | 40 [37–44] | 47 [44–52] | 44 [39–47] | 0.001 | 0.03 |
| Previous myocardial infarction | 5 (20%) | 10 (40%) | 7 (28%) | 0.30 | 0.55 |
| Hypertension | 20 (80%) | 24 (96%) | 22 (88%) | 0.22 | 0.61 |
| Hyperlipidemia | 18 (72%) | 22 (88%) | 24 (96%) | 0.05 | 0.61 |
| Chronic kidney disease | 2 (8%) | 5 (20%) | 5 (20%) | 0.41 | 1.0 |
| Previous stroke | 3 (12%) | 4 (16%) | 2 (8%) | 0.68 | 0.67 |
| Peripheral vascular disease | 4 (16%) | 2 (8%) | 4 (16%) | 0.63 | 0.67 |
| Tobacco use | 7 (28%) | 5 (20%) | 5 (20%) | 0.74 | 1.0 |
| Presenting with acute coronary syndrome | 5 (20%) | 5 (20%) | 7 (28%) | 0.74 | 0.74 |
| Dual anti-platelet therapy with aspirin and clopidogrel prior to arterial access | 14 (56%) | 13 (52%) | 16 (64%) | 0.80 | 0.65 |
| Sulfonylurea | -- | 11 (44%) | 12 (48%) | -- | 1.0 |
| Metformin | -- | 16 (64%) | 16 (64%) | -- | 1.0 |
| Thiazoladinediones | -- | 2 (8%) | 0 | -- | 0.49 |
| Sitagliptin | -- | 2 (8%) | 0 | -- | 0.49 |
| Long-acting nsulin | -- | 9 (36%) | 10 (40%) | -- | 1.0 |
| Ejection fraction | 0.33 | 0.18 | |||
| Normal | 18 (72%) | 16 (67%) | 21 (88%) | ||
| Severely reduced | 2 (8%) | 7 (29%) | 1 (4%) | ||
| Random glucose (mg/dL) | 90 [83–96] | 141 [109–168] | 144 [116–182.] | <0.001 | 0.67 |
| Hemoglobin A1c (%) | 5.8 [5.5–6.0] | 7.1 [6.4–7.9] | 7.0 [6.8–7.8] | <0.001 | 0.78 |
| Platelets (× 109/L) | 198 [139–236] | 193 [171–244] | 194 [169–228] | 0.84 | 0.85 |
| Mean platelet volume (fL) | 9.1 [8.5–9.7] | 8.7 [7.7–9.3] | 9.0 [7.9–9.6] | 0.34 | 0.52 |
| Glomerular filtration rate (mL/min) | 90 [69–140] | 80 [54–89] | 72 [57–96] | 0.19 | 0.69 |
| Low density lipoprotein-cholesterol (mg/dL) | 91 [70–140] | 71 [55–86] | 69 [56–82] | 0.008 | 0.98 |
| High density lipoprotein-cholesterol (mg/dL) | 41 [36–45] | 38 [31–46] | 35 [32–51] | 0.28 | 0.58 |
| Triglyceride (mg/dL) | 133 [85–199] | 138 [109–197] | 154 [106–186] | 0.84 | 0.96 |
| Number of coronary arteries narrowed | |||||
| None | 8 (32%) | 5 (20%) | 7 (28%) | 0.33 | 0.33 |
| 1 vessel | 6 (24%) | 8 (32%) | 3 (12%) | ||
| 2 vessel | 3 (12%) | 8 (32%) | 8 (32%) | ||
| 3 vessel | 8 (32%) | 4 (16%) | 7 (28%) | ||
| Fasting time (hours) | 17.8 [15.1–18.9] | 16.0 [13.5–18.5] | 16.8 [15.6–18.2] | 0.45 | 0.36 |
*
p-value comparing all three groups;
**
p-value comparing continue versus hold groups